Business Context and Reporting Period
This Form 8-K filing by Magenta Therapeutics, Inc. (MGTA) covers the period ending May 6, 2019, with the earliest event reported on May 1, 2019. The registrant is an emerging growth company incorporated in Delaware, with principal executive offices in Cambridge, Massachusetts. The filing details the pricing and closing of an underwritten public offering of common stock.
Key Financial Metrics
The filing reports the following specific financial data regarding the capital raise:
- Shares Sold: 4,887,500 shares of common stock (including 637,500 shares from the full exercise of the underwriters' option).
- Offering Price: $13.25 per share.
- Gross Proceeds: Approximately $64.7 million (calculated from shares and price).
- Net Proceeds: Approximately $60.9 million after underwriting discount and before estimated expenses.
The filing text does not provide clear values for revenue, profit, operating cash flow, margins, debt levels, or liquidity ratios outside of the proceeds from this specific offering.
Material Changes
The primary material change is the significant increase in the company's cash position resulting from the equity offering. The company successfully closed the offering on May 6, 2019, after pricing it on May 1, 2019. The underwriters exercised their option in full to purchase additional shares, increasing the total shares sold beyond the initial 4,250,000 announced at pricing.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the offering's pricing and closing via press releases incorporated by reference. The filing does not contain specific forward-looking guidance, risk factors, or discussion of contingencies beyond the standard disclosure of the offering mechanics. The company is classified as an emerging growth company.
Investor Verification Checklist
- Verify the final use of the approximately $60.9 million in net proceeds as disclosed in subsequent filings or press releases.
- Confirm the exact amount of estimated offering expenses to determine the final net cash inflow.
- Review the attached press releases (Exhibits 99.1, 99.2, and 99.3) for any additional strategic context regarding the capital raise.
- Check for any dilution impact on existing shareholders given the issuance of nearly 4.9 million new shares.